Literature DB >> 27017141

Gianotti-Crosti syndrome as presenting sign of cytomegalovirus infection: A case report and a critical appraisal of its possible cytomegalovirus etiology.

Francesco Drago1, Sanja Javor2, Giulia Ciccarese1, Aurora Parodi1.   

Abstract

Gianotti-Crosti syndrome (GCS) is a self-limiting exanthem of acute onset with a characteristic acral distribution, usually occurring in children. It is characterized by symmetric pink to red-brown papular or papulovesicular lesions that are a few millimetres in diameter, distributed on the face, buttocks and limbs. It may be accompanied by low-grade fever, hepato-splenomegaly and lymphadenopathy. GCS is considered a unique cutaneous response to viral infection, mostly associated with hepatitis B virus and Epstein-Barr virus (EBV), but other viruses, bacterial infections and recent immunizations may be inciting factors. We report a case of a 3-year-old girl presenting generalized, pruritic, papulovesicular eruption on the face and extremities for one month. In our case, GCS was related to cytomegalovirus (CMV) primary infection and may be considered the presenting sign of the infection.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytomegalovirus infection; Etiology; Gianotti-Crosti syndrome (GCS)

Mesh:

Year:  2016        PMID: 27017141     DOI: 10.1016/j.jcv.2016.03.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  2 in total

Review 1.  Gianotti-Crosti syndrome (papular acrodermatitis of childhood) in the era of a viral recrudescence and vaccine opposition.

Authors:  Alexander K C Leung; Consolato Maria Sergi; Joseph M Lam; Kin Fon Leong
Journal:  World J Pediatr       Date:  2019-05-27       Impact factor: 9.186

2.  The Serum Immunoglobulin E Level: Is There a Relationship With the Clinical Course of the Gianotti-Crosti Syndrome?

Authors:  Andrea Bassi; Fausto Pedaci; Teresa Oranges; Chiara Azzari; Luisa Galli; Silvia Ricci; Cesare Filippeschi; Elisabetta Venturini
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.